Executive Cha Gyeong-yeol Acquires 2,000 Shares of SAMIL PHARMACEUTICAL in Open Market Purchase, Signaling Insider Confidence

Non-registered executive Cha Gyeong-yeol acquired 2,000 common shares of SAMIL PHARMACEUTICAL at an average price of 6,770 KRW per share through open market purchase on June 10, 2026. The acquisition represents 0.01% of the total outstanding shares of 21,691,811, indicating a small voluntary investment.
This purchase using personal funds does not affect the company's capital structure or cause any dilution. While insider buying is generally a positive signal for the stock price outlook, the minimal scale suggests limited immediate impact on shareholder value.
[AI Summary]The insider's small open market purchase of 0.01% stake reflects management confidence but has negligible financial impact. No capital allocation changes or dilution occur, and the transaction signifies routine governance alignment.